Last quarter (Q3 2023), Icosavax's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Icosavax's net income was $-22.02M. See Icosavax’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	$ 582.00K	$ 7.80M	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	$ 582.00K	$ 582.00K	$ 7.80M	-	-
Operating Expense	$ 55.62M	$ 95.64M	$ -73.66M	$ 18.71M	$ 5.40M
Operating Income	$ -105.30M	$ -95.06M	$ -65.86M	$ -18.71M	$ -5.40M
Net Non Operating Interest Income Expense	$ -263.00K	$ 3.30M	$ -205.00K	$ -331.00K	$ 101.00K
Other Income Expense	$ -3.89M	$ 403.00K	$ -754.00K	$ 187.00K	-
Pretax Income	$ -96.15M	$ -92.16M	$ -65.46M	$ -18.85M	$ -5.30M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -96.15M	$ -92.16M	$ -65.46M	$ -18.85M	$ -5.97M
Basic EPS	$ -2.82	$ -2.31	$ -3.73	$ -1.82	$ -0.58
Diluted EPS	$ -2.22	$ -2.31	$ -3.73	$ -1.82	$ -0.58
Basic Average Shares	$ 175.79M	$ 39.73M	$ 17.97M	$ 10.24M	$ 10.24M
Diluted Average Shares	$ 175.79M	$ 39.73M	$ 17.97M	$ 10.24M	$ 10.24M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 55.62M	$ 95.64M	$ -73.66M	$ 18.71M	$ 5.40M
Net Income From Continuing And Discontinued Operation	$ -96.51M	$ -91.76M	$ -65.46M	$ -18.85M	$ -5.30M
Normalized Income	$ -38.33M	$ -72.81M	-	$ -19.04M	$ -5.30M
Interest Expense	-	-	-	$ 331.00K	-
EBIT	$ -101.15M	$ -95.46M	$ -65.11M	$ -18.52M	$ -5.40M
EBITDA	$ -102.85M	$ -96.09M	$ -65.01M	$ -18.52M	$ -5.40M

Currency in USD

Icosavax Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing